Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.
| Revenue (TTM) | $690.33M |
| Gross Profit (TTM) | $560.04M |
| EBITDA | $-20.01M |
| Operating Margin | 0.39% |
| Return on Equity | -22.80% |
| Return on Assets | -3.90% |
| Revenue/Share (TTM) | $11.83 |
| Book Value | $12.12 |
| Price-to-Book | 18.16 |
| Price-to-Sales (TTM) | 18.86 |
| EV/Revenue | 18.52 |
| EV/EBITDA | -57.89 |
| Quarterly Earnings Growth (YoY) | 1896.00% |
| Quarterly Revenue Growth (YoY) | 58.00% |
| Shares Outstanding | $59.20M |
| Float | $57.05M |
| % Insiders | 3.60% |
| % Institutions | 104.78% |
Volatility is currently expanding
Glaukos raised its 2026 sales forecast to $775 million to $785 million and set a preliminary 2027 target of $1 billion, after third-quarter sales jumped 58% to $211.0 million. Profit is thinner than the adjusted figures suggest.
Shares of Glaukos Corp (NYSE:GKOS) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results and raised its FY26 sales guidance above estimates.
Glaukos Corporation (GKOS) Q3 2026 Earnings Call Transcript
GKOS shares surge 36.8% in six months, fueled by strong sales, iDose TR and Epioxa expansion, higher guidance and promising clinical developments.
GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.
Glaukos' iDose and Epioxa are driving growth, while recurring treatments, high margins and a broad pipeline support its long-term prospects.
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the launch of Could it be KC?, a new disease awareness and educational campaign launching today with expanding activities planned in 2027 aimed at improving recognition and earlier detection of keratoconus (KC), a rare, progressive, sight-threatening c.
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?
Glaukos' iDose TR momentum and Epioxa launch are driving record growth, higher 2026 guidance and a broader ophthalmology platform.
Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GKOS and any ticker you trade — then tracks every position and per-strategy win rate.
